United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
September 10 2024 - 6:00AM
Business Wire
Report available at corporateresponsibility.unither.com
United Therapeutics Corporation (Nasdaq: UTHR), a public
benefit corporation (PBC), today announced the release of
its 2024 Corporate Responsibility and Public Benefit Report
(Report) covering its FY 2023 progress toward its public
benefit goals and objectives and summarizing its efforts to advance
the interests of patients and other stakeholders.
“Our 2023 financial performance helps set us up for the next
revolutionary wave of growth ahead—our organ manufacturing work,
which you will read more about in this Report,” said Christopher
Causey, Chair of the Nominating and Governance Committee of the
United Therapeutics Board of Directors. “Still, we have seen the
research demonstrating the connections between patient health and
ecosystem health, which is why we maintain our site net zero energy
goal for all new construction, where feasible, and invest in
groundbreaking green building efforts like our Phase Five LEED Gold
certified warehouse in North Carolina. One of the things that I so
value about this company is our commitment to walk the talk.”
As a PBC, United Therapeutics is obligated to report its
progress toward its public benefit purpose—to provide a brighter
future for patients through the development of novel pharmaceutical
therapies, and technologies that expand the availability of
transplantable organs. It pursues this purpose alongside its
obligations to balance the interests of its other stakeholders,
including employees, shareholders, the environment, and the local
communities in which it operates.
United Therapeutics aligns its environmental, social, and
governance (ESG) priorities and performance with its PBC
goals. The following are some highlights from this year’s
Report:
- The company served more than 14,500 patients, including
more than 100 benefiting from its centralized ex vivo lung
perfusion (EVLP) service in 2023, and more than 400 since
service launch;
- Its patient assistance program has enabled more than 32,000
patients secure access to treatments since 2010;
- More than 90 percent of its employees agree,
year-after-year since 2018, that United Therapeutics is a Great
Place to Work;
- With the LEED Gold certification of its Phase Five Warehouse,
approximately 26% of United Therapeutics’ properties are LEED
certified, including its LEED Platinum site net zero commercial
building called the Unisphere;
- United Therapeutics remains a steadfast contributor to, and
consumer of, renewable power through the 7-MW capacity onsite
solar fields it maintains on its properties.
“Patient needs drive everything we do at UT,” said James
Edgemond, Chief Financial Officer and Treasurer of United
Therapeutics. “As Chris notes, we believe in the links across
issues, which is why our PBC goals align with our patients, our
people, and our planet. We manage the balance across our
resources—human, financial, and environmental—to achieve better,
long-lasting outcomes.”
Alongside the publication of this Report, United Therapeutics
also announced the launch of its updated corporate responsibility
website. This site includes two new sections: Reports and Other
Resources, which links to documents of interest to stakeholders
including topic overviews, policies, and more, and Impact Stories,
which showcases the creative spark indicative of UT employees.
Find the full report at corporateresponsibility.unither.com.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use
our enthusiasm, creativity, and persistence to innovate for the
unmet medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun; we do
good. We are the first publicly traded biotech or pharmaceutical
company to take the form of a public benefit corporation. Our
public benefit purpose is to provide a brighter future for patients
through (a) the development of novel pharmaceutical therapies; and
(b) technologies that expand the availability of transplantable
organs.
You can learn more about what it means to be a PBC here:
unither.com/PBC.
Forward-looking Statements
Statements included in this press release that are not
historical in nature are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, statements
regarding progress toward achieving our public benefit purpose and
furthering the interests of other stakeholders (including
employees, shareholders, the environment, and local communities in
which we operate): our progress toward a future where no patient
gets left behind; our next revolutionary wave of growth ahead—our
organ manufacturing work; our efforts to steward our resources —
human, financial, and environmental — to get better, long-lasting
outcomes; our net zero energy goal for all new construction, where
feasible; our commitment to taking meaningful, evidence-based
actions; and our goals of innovating for the unmet medical needs of
our patients and to benefit our other stakeholders and furthering
our public benefit purpose of developing novel pharmaceutical
therapies and technologies that expand the availability of
transplantable organs. These forward-looking statements are subject
to certain risks and uncertainties, such as those described in our
periodic reports filed with the Securities and Exchange Commission,
which could cause actual results to differ materially from
anticipated results. Consequently, such forward-looking statements
are qualified by the cautionary statements, cautionary language and
risk factors set forth in our periodic reports and documents filed
with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
and Current Reports on Form 8-K. We claim the protection of the
safe harbor contained in the Private Securities Litigation Reform
Act of 1995 for forward-looking statements. We are providing this
information as of September 10, 2024, and assume no obligation to
update or revise the information contained in this press release
whether as a result of new information, future events, or any other
reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910010301/en/
Catherine Sheehy at (240) 398-3504 (sustainability) Dewey
Steadman at (202) 919-4097 (investors/media)
https://ir.unither.com/contact-uthr/
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Sep 2024 to Oct 2024
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Oct 2023 to Oct 2024